Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTION-1 trial of RYZ101 versus standard of care in progressed SSTR-positive GEP-NET after prior lutetium-177 SSA therapy
NL-OMON56219Phase 3Not yet recruiting
- Sponsor
- RayzeBio
- Start
- May 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Gastroenteropancreatic Carcinoid Tumor comparing RYZ101 with Investigator-selected standard of care (2 arms). Primary endpoint: Centrally confirmed progression-free survival. Planned start May 2023; status: not yet recruiting.
02
Drugs
actinium-225 dotatate
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on NL-OMON56219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56219.